Treatment News : Selzentry (Maraviroc) Fails to Best Truvada as First-Line Therapy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 30, 2014

Selzentry (Maraviroc) Fails to Best Truvada as First-Line Therapy

AIDS 2014Selzentry (maraviroc) failed in a head-to-head with Truvada (tenofovir/emtricitabine) as a first-line treatment for HIV when each were paired with Prezista (ritonavir-boosted darunavir), aidsmap reports. Researchers from the double-blind Phase II MODERN study presented their findings at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia.

The investigators enrolled over 1,400 treatment-naive HIV-positive adults. After testing to see if the participants were susceptible to Selzentry, the pool was narrowed to 797 people who were equally randomized to receive Prezista paired with either Selzentry or Truvada. With the treatment continuing for 96 weeks, the researchers were ultimately looking to see the proportion of each study arm that achieved an undetectable viral load at the 48-week mark.

Seventy-seven percent of those in the Selzentry arm had a fully suppressed virus by 48 weeks, compared with 87 percent of those in the Truvada arm. Those who started the study with a low viral load wound up with similar rates of viral suppression: a respective 80 and 89 percent in the Selzentry and Truvada arms. However, starting with a high viral load led to worse outcomes for those in the Selzentry group: Just 65 percent had an undetectable viral load after 48 weeks, compared with 80 percent in the Truvada group.

Ultimately, the researchers concluded that the Selzentry regimen failed to qualify for “non-inferior” status when compared with the Truvada combination, and the trial was discontinued early.

To read the aidsmap story, click here.

To read the conference abstract, click here.

Search: Selzentry, maraviroc, Truvada, tenofovir, emtricitabine, Prezista, ritonavir, darunavir, MODERN, 20th International AIDS Conference, AIDS 2014.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.